Effects of whole-body electromyostimulation training on glycaemia and physical performance in adults with double diabetes

Effects of whole-body electromyostimulation training on glycaemia and physical performance in adults with double diabetes - WHEDD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00034560

Enrollment

Registered

2024-07-09

Start date

2027-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Double Diabetes (ICD10, E13) E13

Interventions

Group 1: Whole-body electromyostimulation (4 months): A 4-month standard WB-EMS application of all large muscle groups (total area of the electrodes: 2800 cm2) 1.5x 20 min week (e.g. every Tuesday and

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Legally competent men and women with clinically manifest T1DM At least one additional criterion of metabolic syndrome according to the International Diabetes Federation, i.e. Abdominal circumference =94 cm (men) or =80 cm (women) Triglyceride values =150 mg/dl or treatment already initiated HDL cholesterol 6.5%

Exclusion criteria

Exclusion criteria: Cardiovascular diseases, in particular high-grade cardiac arrhythmia / atrial fibrillation / pacemaker or heart failure > NYHA1 High-grade (drug-treated) obstructive and restrictive lung disease (asthma / COPD / PHT) epilepsy Severe circulatory disordersGFR<60; diabetic nephropathy Regular (= 1TE/week) strength training in the last 8 weeks Contraindications for the use of MRI Absolute contraindications for WB-EMS Anticipated absence = 3 weeks during the intervention period

Design outcomes

Primary

Measure	Time frame
Time in Range (TIR; Glucose 70-180 mg/d), baseline assessment (before the intervention) and 4-month control assessment (4-month FU)	—

Secondary

Measure	Time frame
Time below the target range (TBR; 180 mg/dL), at baseline and 4 month FU Fasting glucose, insulin, cortisol, triglycerides, total-, HDL-, LDL-cholesterol, at baseline and 4 month FU Resting blood pressure (MAP), at baseline and 4 month FU Total and regional body fat mass, at baseline and 4 month FU Total and regional lean body mass, at baseline and 4 month FU Visceral fat volume, at baseline and 4 month FU intramuscular fat accumulation (intramuscular adipose tissue: IMAT), at baseline and 4 month FU Isokinetic maximum strength of the hip-/leg extensors, isom. trunk strength, at baseline and 4 month FU Endurance capacity, at baseline and 4 month FU Resting metabolic rate, at baseline and 4 month FU Attendance, drop-out, withdrawals, continuously during the intervention Adverse events, serious adverse events, continuously during the intervention	—

Measure

Time frame

Time below the target range (TBR; 180 mg/dL), at baseline and 4 month FU Fasting glucose, insulin, cortisol, triglycerides, total-, HDL-, LDL-cholesterol, at baseline and 4 month FU Resting blood pressure (MAP), at baseline and 4 month FU Total and regional body fat mass, at baseline and 4 month FU Total and regional lean body mass, at baseline and 4 month FU Visceral fat volume, at baseline and 4 month FU intramuscular fat accumulation (intramuscular adipose tissue: IMAT), at baseline and 4 month FU Isokinetic maximum strength of the hip-/leg extensors, isom. trunk strength, at baseline and 4 month FU Endurance capacity, at baseline and 4 month FU Resting metabolic rate, at baseline and 4 month FU Attendance, drop-out, withdrawals, continuously during the intervention Adverse events, serious adverse events, continuously during the intervention

—

Countries

Germany

Contacts

Public ContactSimon von Stengel

Institut für Radiologie, Universitätsklinikum Erlangen, Deutschland

simon.von.stengel@fau.de+49 9131 852 3999

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026